Immunic, Inc. operates as a clinical-stage biopharmaceutical enterprise dedicated to the discovery, development, and commercialization of novel, oral immunology therapies designed to treat chronic inflammatory and autoimmune diseases. The company's proprietary pipeline focuses heavily on developing small-molecule inhibitors—such as its lead asset, vidofludimus calcium—that target specific intracellular pathways to modulate immune responses in conditions like relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and ulcerative colitis. By advancing these targeted oral treatments through rigorous global clinical trials, the enterprise aims to provide patients with safer, more convenient therapeutic alternatives to existing injectable biologic therapies.